Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 12,34 € (+80,15 %). La mediana es de 13,65 € (+99,27 %).
| Comprar |
15 |
| Mantener |
6 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Iovance Biotherapeutics raises annual guidance after strong demand for Amtagvi and Proleukin
Strong market demand for the cancer therapies Amtagvi (Lifileucel) and Proleukin has led Iovance Biotherapeutics to significantly raise its annual forecast. The company is expanding its TIL therapy platform and broadening the clinical pipeline for additional solid tumors. Despite a weak overall market, investors are drawing the stock higher, signaling company-specific momentum. » Más en finanzen.net
Iovance raises 2026 revenue forecast after strong demand for Amtagvi
Iovance raised its 2026 revenue forecast to $410–420 million, supported by rising U.S. demand for Amtagvi and Proleukin. Shorter production times and more than 110 treatment centers are driving growth and pushed the stock up about 10% to a 52-week high. The business remains based on tumor-infiltrating lymphocytes (TIL), which are increasingly entering clinical practice for solid tumors. » Más en finanzen.net
Iovance Biotherapeutics accelerates revenue growth after successful launch of Amtagvi
Iovance Biotherapeutics is commercializing Amtagvi, the world’s first approved personalized TIL cell therapy for advanced melanoma. Rapid onboarding of specialized treatment centers and rising patient demand are driving dynamic revenue acceleration in the current fiscal year. Analysts view the first-mover advantage and the successful market entry as drivers for further operational growth. » Más en finanzen.net
Iovance Biotherapeutics reaches 52-week high at $9.36
Iovance Biotherapeutics shares rose to a 52-week high of $9.36, delivering a year-to-date return of 215% and nearly a 279% gain over the past year; market capitalization is around $4.2 billion. In Q2 2026 the company reported record revenue of $99.31 million, driven by strong sales of the cancer therapy Amtagvi ($91 million), and an adjusted loss of $0.11 per share, beating expectations. UBS raised its price target to $7.00 (rating: neutral), TD Cowen increased its target to $10.00 and maintained buy; InvestingPro currently considers the stock overvalued. » Más en de.investing.com
Iovance reports record Q2 revenue and reviews 2026 guidance on strong Amtagvi demand
Iovance reported record Q2 revenue of about $99.3 million, a 66% year-over-year increase driven by strong Amtagvi sales (U.S. Amtagvi ~$91M) and Proleukin ~$9M. Gross margin improved to 56% on higher volumes, manufacturing efficiencies and cost optimisation, while R&D expenses fell for a fourth consecutive quarter. Management is reviewing its 2026 revenue guidance of $350–370 million with an updated outlook expected in Q3, and continues expanding its treatment network to over 95 centres (forecasting at least 110 by year-end). The company finished the quarter with roughly $304 million in cash and is advancing multiple late‑stage clinical programmes and international regulatory submissions. » Más en finance.yahoo.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 107,24 M | 86,57 % |
| Beneficio bruto | 64,84 M | 162,57 % |
| Beneficio neto | -19,66 M | 74,71 % |
| EBITDA | -10,74 M | 83,90 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 3141,83 M € |
Número de acciones | 462,66 M |
Máximo/mínimo de 52 semanas | 13,98 € - 1,89 € |
| Dividendos | No |
Beta | 0,76 |
Ratio P/E | -14,08 |
Ratio PEG | -0,15 |
Ratio P/B | 4,19 |
Ratio P/S | 9,11 |
Perfil de la empresa
Iovance Biotherapeutics, Inc., una empresa de biotecnología en fase clínica, se dedica al desarrollo y la comercialización de productos de inmunoterapia contra el cáncer para aprovechar el poder del sistema inmunitario del paciente y erradicar las células cancerosas. Tiene seis estudios clínicos de fase 2 en curso, entre ellos C-144-01, de su principal candidato a producto, lifileucel, para el tratamiento del melanoma metastásico; C-145-04, de su candidato a producto lifileucel para el cáncer cervical recurrente, metastásico o persistente; y C-145-03, de su candidato a producto LN-145, para el carcinoma de células escamosas de cabeza y cuello recurrente y/o metastásico. Iovance Biotherapeutics, Inc. mantiene colaboraciones y acuerdos de licencia con H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; y Novartis Pharma AG. La empresa era conocida anteriormente como Lion Biotechnologies, Inc. y cambió su nombre a Iovance Biotherapeutics, Inc. en junio de 2017. Iovance Biotherapeutics, Inc. se constituyó en 2007 y tiene su sede en San Carlos, California.
| Nombre | Iovance Biotherapeutics |
| CEO | Frederick G. Vogt |
| Sede | San Carlos,
ca Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Biotecnología |
| Salida a bolsa | 15/10/2010 |
| Empleados | 975 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | IOVA |
London Stock Exchange | 0JDK.L |
Frankfurt | 2LB.F |
Düsseldorf | 2LB.DU |
London | 0JDK.L |
München | 2LB.MU |